This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
More From The Market Online
Omega Oil & Gas kicks off play-defining drilling campaign at Canyon-3
Omega Oil & Gas has commenced drilling operations at Canyon-3, another key step in confirming the…
- Colin Sandell-Hay
- 3 mins
- 31 July 2026 16:12 (AEST)
HotCopper Highlights, Week 31: Pilbara Minerals, BrainChip and 4DMedical spark fresh investor interest
Pilbara Minerals, Dateline Resources and Strike Energy top this week's most viewed stocks, while 4DMedical, Liontown…
- Seja Al Zaidi
- 2 mins
- 31 July 2026 15:25 (AEST)
Ariana Resources earns US$3.7M from further asset sale in Turkiye
Ariana Resources has sold its legacy 9.9% interest in the Kiziltepe Sector in Türkiye to Proccea…
- Colin Sandell-Hay
- 2 mins
- 31 July 2026 15:16 (AEST)
Meteoric Resources unveils confidence boosting Caldeira DFS
Meteoric Resources has unveiled a DFS for its Caldeir rare earth project in Brazil which has…
- Colin Sandell-Hay
- 3 mins
- 31 July 2026 14:24 (AEST)
